Evaluation of Heparin Rebound in Cardiac Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01675817|
Recruitment Status : Unknown
Verified September 2012 by Ravi Taneja, Lawson Health Research Institute.
Recruitment status was: Recruiting
First Posted : August 30, 2012
Last Update Posted : September 28, 2012
Recent work has shown that heparin rebound is common after cardiac surgery.
The exact doze of protamine required to neutralize heparin at the end of CPB is unknown. Besides, the precise doze of protamine to treat heparin rebound is also unknown. It is also unknown if precise titration of protamine perioperatively in cardiac surgery can influence transfusion requirements after cardiac surgery.
|Condition or disease|
This study will assess how much protamine is required to neutralize residual heparin perioperatively in cardiac surgery through measurement of functional assays of heparin (anti-Xa and anti-IIa levels). In the first phase of this study, protamine titration assays will be carried out on normal pooled plasma incubated with heparin in the laboratory.
Once the correct dose of protamine required to neutralize the heparin is established in the laboratory, the second phase will begin. Herein, plasma samples from patients undergoing cardiac surgery (with anticoagulation with two different commercial preparations of heparin) will be evaluated for residual heparin (Anti-Xa and anti-IIa levels). Protamine titration assays wil then be carried out in vitro to assess neutralization of heparin.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Evaluation of Heparin Rebound in Cardiac Surgery|
|Study Start Date :||April 2011|
|Estimated Primary Completion Date :||March 2013|
|Estimated Study Completion Date :||March 2013|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01675817
|Contact: Ravi Taneja, MD, FRCPC||519-685-8500 ext email@example.com|
|Dr. Ravi Taneja||Recruiting|
|London, Ontario, Canada, N6A 5A5|
|Principal Investigator:||Ravi Taneja, MD, FRCPC||Lawson Health Research Institute|